Workflow
Burning Rock Reports First Quarter 2025 Financial Results
BNRBurning Rock Dx(BNR) GlobeNewswire·2025-06-06 07:31

Core Insights - Burning Rock Biotech Limited reported a revenue of RMB 133.1 million (US18.3million)forQ12025,markinga5.9 18.3 million) for Q1 2025, marking a 5.9% increase from RMB 125.6 million in Q1 2024 [3] - The company achieved a gross profit of RMB 97.4 million (US 13.4 million) for the same period, representing a 13.7% increase from RMB 85.7 million in Q1 2024, with a gross margin of 73.2% [5][8] - The net loss for Q1 2025 was RMB 13.5 million (US1.9million),asignificantreductionfromanetlossofRMB121.5millioninQ12024[10]FinancialPerformance−Revenuefromthecentrallaboratorybusinessdecreasedby19.6 1.9 million), a significant reduction from a net loss of RMB 121.5 million in Q1 2024 [10] Financial Performance - Revenue from the central laboratory business decreased by 19.6% to RMB 38.3 million (US 5.3 million) in Q1 2025, primarily due to a reduction in the number of tests [6] - Revenue from the in-hospital business increased by 0.5% to RMB 57.7 million (US7.9million),drivenbygrowthinsalesvolume[6]−Revenuefrompharmaresearchanddevelopmentservicessurgedby79.9 7.9 million), driven by growth in sales volume [6] - Revenue from pharma research and development services surged by 79.9% to RMB 37.1 million (US 5.1 million), attributed to increased development and testing services [6] Cost Management - Cost of revenues decreased by 10.6% to RMB 35.7 million (US4.9million)inQ12025,aligningwiththerevenuedeclineinthecentrallaboratorybusiness[4]−Operatingexpensesweresignificantlyreducedby46.8 4.9 million) in Q1 2025, aligning with the revenue decline in the central laboratory business [4] - Operating expenses were significantly reduced by 46.8% to RMB 112.6 million (US 15.5 million) due to budget control measures and headcount reduction [9] - Research and development expenses decreased by 38.8% to RMB 40.4 million (US5.6million)[14]GrossMarginAnalysis−Non−GAAPgrossprofitforQ12025wasRMB100.7million(US 5.6 million) [14] Gross Margin Analysis - Non-GAAP gross profit for Q1 2025 was RMB 100.7 million (US 13.9 million), an 8.3% increase from RMB 93.0 million in Q1 2024, with a non-GAAP gross margin of 75.6% [8][16] - The gross margin for the central laboratory business improved to 84.1% in Q1 2025 from 77.7% in Q1 2024, driven by cost optimization [5] Cash Position - As of March 31, 2025, the company had cash, cash equivalents, and restricted cash totaling RMB 497.4 million (US$ 68.5 million) [10]